April A N Rose

15PUBLICATIONS
93CO-AUTHORS
Medical virologyMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 06, 2026
mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathway.

|Jan 03, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.

April A N Rose, Jennifer Maxwell, Emmanuelle Rousselle

|Jan 27, 2025
Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers.

Matthew Dankner, Emmanuelle Rousselle, Sarah Petrecca

|May 13, 2024
The evolving treatment landscape for BRAF-mutated non-small cell lung cancer.

Matthew Dankner, Jennifer Maxwell, April A N Rose

|Mar 29, 2024
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study.

Soumaya Labidi, Nicholas Meti, Reeta Barua

|Jan 10, 2024
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.

Melody Riaud, Jennifer Maxwell, Isabel Soria-Bretones

Pageof 3

Frequent Collaborators

4 joint publications

David W Cescon

3 joint publications

Matthew Dankner

3 joint publications

Marcus O Butler

3 joint publications

Anna Spreafico